Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P14091

UPID:
CATE_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P14091; Q5TZ01; Q5TZ02; Q9NY58; Q9UCE3; Q9UCE4

BACKGROUND:
The protein Cathepsin E, with the unique identifier P14091, is implicated in several critical biological processes. It is believed to have a significant role in immune function, particularly in the processing of antigenic peptides essential for MHC class II-mediated antigen presentation. This protein may also be involved in the depletion of lymphocytes in the thymus and play a role in the degeneration of neurons and activation of glial cells in the brain.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Cathepsin E holds promise for the development of novel therapeutic strategies. Given its potential role in immune response and neurological processes, targeting Cathepsin E could lead to breakthrough treatments for diseases associated with these areas.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.